Ultragenyx gains exclusive rights for Regenxbio's NAV vectors

22 October 2018

US biotech Regenxbio (Nasdaq: RGNX) saw its share drop 3.9% to $60.81 by mid-morning, despite announcing a licensing deal for its technology.

Ultragenyx Pharmaceutical (Nasdaq: RARE)I has exercised an option for an exclusive worldwide license to Regenxbio’s NAV vectors, including NAV AAV9, for the treatment of CDKL5 Deficiency Disorder (CDD), with the news also pushing Utragenyx’ shares down 3.91% to $56.09.

Under the terms of the license, Regenxbio will receive an undisclosed upfront payment, ongoing fees, milestone payments and royalties on net sales of products incorporating NAV Vectors. The option exercised by Ultragenyx is the final remaining disease indication option under the 2015 license agreement between Regenxbio and Dimension Therapeutics, a wholly-owned subsidiary of Ultragenyx.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK